GC 4711

Drug Profile

GC 4711

Alternative Names: GC-4711

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galera Therapeutics
  • Class Antifibrotics; Antineoplastics; Small molecules
  • Mechanism of Action Antioxidants; Superoxide dismutase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 13 Nov 2017 Galera Therapeutics plans the phase I GTO-003 trial of GC 4711 in comparison with GC 4419 in Healthy Volunteers in Australia (PO, Capsule) (NCT03099824)
  • 25 Sep 2017 Phase-I clinical trials in an Undefined indication (In volunteers) in Australia (IV) (NCT03194139)
  • 25 Sep 2017 Preclinical trials in an Undefined indication (In volunteers) in Australia (IV) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top